Valneva SE
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INRLF research report →
About the company
Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are currently lacking. Its existing range of vaccines for international travelers includes IXIARO, an inactivated, Vero cell culture-based immunization designed to actively protect against Japanese encephalitis. Another key product is DUKORAL, an oral vaccine intended to prevent diarrhea caused by Vibrio cholera and/or the heat-labile toxin-producing Enterotoxigenic Escherichia coli.
- CEO
- Thomas Lingelbach
- IPO
- 2010
- Employees
- 713
- HQ
- Saint-Herblain, FR
Price Chart
- Market Cap
- $496.87M
- P/E
- -2.88
- P/S
- 2.84
- P/B
- 5.24
- EV/EBITDA
- -6.32
- Div Yield
- 0.00%
- Gross Margin
- 29.46%
- Op Margin
- -68.81%
- Net Margin
- -88.30%
- ROE
- -106.22%
- ROIC
- -36.00%
- Revenue
- $174.66M · 3.00%
- Net Income
- $-115,192,000 · -840.57%
- EPS
- $-0.68 · -630.40%
- Op Income
- $-81,631,000
- FCF YoY
- 31.42%
- 52W High
- $6.28
- 52W Low
- $2.46
- 50D MA
- $2.70
- 200D MA
- $4.07
- Beta
- 1.40
- Avg Volume
- 203
Get TickerSpark's AI analysis on INRLF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our INRLF coverage
Recent articles, reports, and earnings notes.
No research on INRLF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INRLF report →Similar companies
Peers in the same neighborhood.